A Weight Loss Drug Is Showing Surprising Promise for Alcohol Addiction—Here's What We Know

Semaglutide, the active ingredient in popular weight loss medications like Ozempic and Wegovy, is showing remarkable promise as a treatment for alcohol addiction, with some patients experiencing more than 50% reduction in relapse risk. This unexpected discovery emerged from patients who noticed their desire for alcohol dramatically decreased while taking the medication for weight loss, sparking new research into how these drugs might revolutionize addiction treatment.

How Does Semaglutide Affect Alcohol Cravings?

The mechanism behind semaglutide's effect on alcohol consumption appears to involve the brain's reward centers. "Part of how these drugs may work is how they impact the reward centers in the brain," said Dr. Leslie Heinberg of Cleveland Clinic. "People just don't find the same reward when they drink, say, a glass of wine, than they used to." Semaglutide belongs to a class of medications called glucagon-like peptide-1 (GLP-1) receptor agonists, which millions of Americans use to help control hunger and blood sugar levels.

Betsy Spiegel, who has been taking semaglutide-based medication, experienced this firsthand. After losing 80 pounds on the drug, she discovered an unexpected benefit: her desire for alcohol nearly disappeared. "I almost quit drinking completely because it just did not taste good to me anymore," Spiegel explained. One glass of wine would last her all night, and she might not even finish it.

What Does the Research Show About Effectiveness?

Dr. Nora Volkow, director of the National Institute on Drug Abuse, co-authored a 2024 study exploring semaglutide's link to alcohol use disorder. The research found that patients with obesity or type 2 diabetes who took the drug saw significantly lower relapse risks. "Semaglutide reduced both the incidence as well as the severity of alcohol use disorder," Volkow said.

A clinical trial in early 2025 demonstrated that for adults with alcohol use disorder, semaglutide significantly reduced both alcohol cravings and heavy drinking episodes. The findings are particularly significant given that alcohol use disorder contributes to an estimated 178,000 deaths annually in the United States, and current treatment options remain limited.

Medical professionals are already seeing real-world applications. Stefanee Clontz, director of operations at Hydra+, a medical wellness spa in Atlanta that offers semaglutide treatments, reported that some clients use the medication specifically to manage their alcohol intake. She described one client who "is actually down to her goal weight now but still comes in once a week for an injection because it helps her drink less."

What Other Innovative Treatments Are Emerging?

Beyond semaglutide, researchers are exploring several cutting-edge approaches to alcohol addiction treatment that could transform recovery outcomes:

• Transcranial Magnetic Stimulation (TMS): This non-invasive treatment uses magnetic stimulation to activate specific brain areas and is being tested to reduce cravings and enhance self-control among individuals with long-term alcohol use disorder history.
• Gene Therapy: This experimental approach involves altering genes in the dopamine system that controls reward and pleasure, potentially reducing cravings and preventing relapse by modifying the biological mechanisms behind addiction.
• Traditional Therapies: Cognitive behavioral therapy (CBT), dialectical behavior therapy (DBT), and relapse prevention skills continue to support long-term sobriety as part of comprehensive treatment programs.

These innovative treatments are showing promising results in clinical trials, with researchers reporting significant reductions in cravings and improvements in self-control. "Both alcohol use disorder, drug addictions have very, very high morbidity and mortality and economic costs, and we have very limited treatments," Volkow explained, emphasizing the urgent need for new therapeutic options.

Are There Safety Concerns With Off-Label Use?

Despite the promising results, experts urge caution regarding off-label use of semaglutide for alcohol addiction. The Food and Drug Administration has not approved semaglutide for treating alcohol use disorders, and more research is needed to establish proper dosing, treatment duration, and safety protocols.

Volkow cautioned against off-label use until safety and efficacy have been confirmed by scientific research. "People are prescribing them, so there is an urgency to move forward as fast as possible so we can determine and guide people — yes this is valuable or non-valuable," she said.

Additional trials are currently underway across the country to explore semaglutide's potential in treating alcohol use disorders and other addictive behaviors. Novo Nordisk, the maker of Ozempic, has sponsored studies examining semaglutide's effect on alcohol consumption, though the company stated the main purpose was to assess effects on liver health.

"Having a whole toolbox of options that we can offer patients, I think, is really essential in order to address the complexity of these diseases," Heinberg noted, highlighting the importance of multiple treatment approaches for alcohol addiction recovery. As research continues, these innovative treatments may become essential tools in fighting alcohol addiction, offering renewed hope for the approximately 28.9 million Americans who battled alcohol use disorder in 2023.